Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
University of Colorado, Denver
M.D. Anderson Cancer Center
Northwell Health
Age
21–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men ≥ 21 years of age with a life expectancy estimated to be \> 10-years.
Diagnosis of adenocarcinoma of the prostate confirmed by MSKCC or participating site pathology review.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Prostate cancer clinical stage T1c-T2a
PSA \< 10ng/mL (this will be the PSA level prompting the prostate biopsy)
MRI evidence of one-sided disease performed within 3 months of registration
Prostate size \<60 cc at time of treatment- if the prostate is larger, hormonal therapy is allowed to achieve the required size Screening biopsy parameters:
Minimum of 10 biopsy cores
Gleason grade 7 in two cores or less, with no primary Gleason grade 4 or 5 in any cores
Unilateral cancer (only right-sided or left-sided, not bilateral)
No more than 50 % cancer in any one biopsy core
No more than 25 % of cores containing cancer
Repeat transrectal or transperineal prostate biopsy that must meet the following parameters:
Minimum of 12 biopsy cores
Unilateral cancer (only right-sided or left-sided, not bilateral)
Gleason grade 7 in two cores or less, with no primary Gleason grade 4 or 5 in any cores
No more than 50 % cancer in any one biopsy core
No more than 25 % of cores containing cancer
You may not be if
Medically unfit for anesthesia
Evidence or suspicion of extracapsular extension on MRI
IPSS score \> 18
Unable to receive MRI
Prior radiotherapy for the current disease
Clareo Health | Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer
